SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 123,343.88 |
Enterprise Value ($M) | 117,227.98 |
Book Value ($M) | 16,409.60 |
Book Value / Share | 63.90 |
Price / Book | 7.52 |
NCAV ($M) | 3,472.80 |
NCAV / Share | 13.52 |
Price / NCAV | 35.52 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.03 |
Return on Assets (ROA) | -0.02 |
Return on Equity (ROE) | -0.03 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.35 |
Current Ratio | 2.69 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 9,596.40 |
Assets | 22,533.20 |
Liabilities | 6,123.60 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 11,020.10 |
Operating Income | 4,603.80 |
Net Income | -535.60 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -492.60 |
Cash from Investing | -3,770.00 |
Cash from Financing | -1,494.90 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Capital World Investors | |||
13G/A | Fmr Llc | |||
13G/A | Vanguard Group Inc | 8.65 | 3.41 | |
13G | BlackRock, Inc. | 8.50 | -9.74 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
278,907 | 1,086,342 | 25.67 | |
307,342 | 1,292,159 | 23.79 | |
196,482 | 1,041,090 | 18.87 | |
241,432 | 1,019,194 | 23.69 | |
(click for more detail) |
Similar Companies | |
---|---|
VIGL – Vigil Neuroscience, Inc. | VIR – Vir Biotechnology, Inc. |
VOR – Vor Biopharma Inc. | VTRS – Viatris Inc. |
VTYX – Ventyx Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io